Advertisement

Polatuzumab Vedotin-piiq Plus R-CHP vs R-CHOP in Previously Untreated DLBCL: POLARIX Trial
Posted: 03/03/2022 | By: Matthew Stenger

Question 1 of 5

For the primary analysis, outcomes were:

Choose 1

A
A median progression-free survival rate of 76.7 months in the pola-R-CHP group vs 70.2 months in the R-CHOP group
B
A 2-year event-free survival of 76.7% in the pola-R-CHP group vs 70.2% in the R-CHOP group
C
A 2-year progression-free survival rate of 76.7% in the pola-R-CHP group vs 70.2% in the R-CHOP group
D
A 2-year event-free survival of 78.0% in the pola-R-CHP group vs 74.0% in the R-CHOP group

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage